IV 
117TH CONGRESS 
1ST SESSION 
H. RES. 391 
Supporting the designation of July 21, 2021, as ‘‘Glioblastoma Awareness 
Day’’. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 12, 2021 
Mr. MAST (for himself, Ms. SCHAKOWSKY, Mr. LANGEVIN, and Mr. GALLA-
GHER) submitted the following resolution; which was referred to the Com-
mittee on Energy and Commerce 
RESOLUTION 
Supporting the designation of July 21, 2021, as 
‘‘Glioblastoma Awareness Day’’. 
Whereas approximately 13,000 new cases of glioblastoma will 
be diagnosed in the United States in 2021; 
Whereas glioblastoma is— 
(1) the most common malignant, cancerous brain 
tumor, accounting for approximately half of all primary 
malignant brain tumors; and 
(2) the most aggressive, complex, difficult to treat, 
and deadly type of brain tumor; 
Whereas it is estimated that more than 10,000 individuals in 
the United States will succumb to glioblastoma every 
year; 
VerDate Sep 11 2014 
00:09 May 13, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR391.IH
HR391
pbinns on DSKJLVW7X2PROD with BILLS
•HRES 391 IH 
Whereas the 5-year survival rate for glioblastoma patients is 
only 7.2 percent and the median length of survival for 
glioblastoma patients is only 8 months; 
Whereas glioblastoma is described as a disease that affects 
the ‘‘essence of self’’, as the treatment and removal of 
glioblastoma presents significant challenges due to the 
uniquely complex and fragile nature of the brain, the pri-
mary organ in the human body that controls not only 
cognitive ability but also the actions of every organ and 
limb; 
Whereas relative to other types of cancers, brain cancer 
has— 
(1) the highest per-patient initial cost of care, with 
an annualized mean net cost of care approaching 
$150,000; and 
(2) the highest annualized mean net costs for last- 
year-of-life care, with a cost of between $135,000 and 
$210,000 per patient, depending on the age and gender 
of a patient; 
Whereas although research advances may fuel the develop-
ment of new treatments for glioblastoma, challenging ob-
stacles to accelerating progress toward new treatments 
for glioblastoma remain and there are no screening or 
early detection methods; 
Whereas although glioblastoma was first described in medical 
and scientific literature in the 1920s, and despite its dev-
astating prognosis, only 4 drugs and 1 medical device 
have been approved by the Food and Drug Administra-
tion to treat glioblastoma since the 1920s and the mor-
tality rates associated with glioblastoma have changed lit-
tle during the past 30 years; 
VerDate Sep 11 2014 
00:09 May 13, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR391.IH
HR391
pbinns on DSKJLVW7X2PROD with BILLS
•HRES 391 IH 
Whereas as a promising first step since the first Glioblastoma 
Awareness Day, the National Cancer Institute established 
the Glioblastoma Therapeutics Network (referred to in 
this preamble as ‘‘GTN’’) in 2020, as part of a national 
infrastructure to enhance and support the discovery and 
development of glioblastoma therapies, with an initial 
$6,000,000 available for multi-institutional GTN teams 
to drive therapeutic agents through pre-clinical studies 
and early-phase clinical trials necessary to rapidly evalu-
ate potential treatments to advance toward cures and im-
proved quality of life; and 
Whereas there is a need for greater public awareness of glio-
blastoma, including awareness of both— 
(1) the urgent unmet medical needs of glioblastoma 
patients; and 
(2) the opportunities for research and treatment ad-
vances for glioblastoma: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) supports the designation of ‘‘Glioblastoma 
Awareness Day’’; 
(2) encourages increased public awareness of 
glioblastoma; 
(3) honors the individuals who have lost their 
lives to glioblastoma, a devastating disease, or are 
currently living with it; 
(4) supports efforts to develop better treat-
ments for glioblastoma that will improve the long- 
term prognosis and quality of life of individuals di-
agnosed with the disease; 
VerDate Sep 11 2014 
00:09 May 13, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR391.IH
HR391
pbinns on DSKJLVW7X2PROD with BILLS
•HRES 391 IH 
(5) expresses its support for the individuals who 
are battling brain tumors, as well as the families, 
friends, and caregivers of those individuals; 
(6) urges a collaborative approach to brain 
tumor research, which is a promising means of ad-
vancing the understanding and treatment of glio-
blastoma; and 
(7) encourages continued Federal investments 
in glioblastoma research and treatments, including 
through the Glioblastoma Therapeutics Network and 
other existing brain tumor research resources. 
Æ 
VerDate Sep 11 2014 
00:09 May 13, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR391.IH
HR391
pbinns on DSKJLVW7X2PROD with BILLS